SKSathish Kumar

Sathish Kumar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sathish Kumar has a total of 82 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    Gain-of-function human UNC93B1 variants cause systemic lupus erythematosus and chilblain lupus

    by Clémence David, Carlos A. Arango-Franco, Mihaly Badonyi, Julien Fouchet, Gillian I. Rice, Blaise Didry-Barca, Lucie Maisonneuve, Luis Seabra, Robin Kechiche, Cécile Masson, et al.

    UNC93B1 is a transmembrane domain protein mediating the signaling of endosomal Toll-like receptors (TLRs). We report five families harboring rare missense substitutions (I317M, G325C, L330R, R466S, and R525P) in UNC93B1 causing systemic lupus erythematosus (SLE) or chilblain lupus (CBL) as either autosomal dominant or autosomal recessive traits. As for a D34A mutation causing murine lupus, we recorded a gain of TLR7 and, to a lesser extent, TLR8 activity with the I317M (in vitro) and G325C (in vitro and ex vivo) variants in the context of SLE. Contrastingly, in three families segregating CBL, the L330R, R466S, and R525P variants were isomorphic with respect to TLR7 activity in vitro and, for R525P, ex vivo. Rather, these variants demonstrated a gain of TLR8 activity. We observed enhanced interaction of the G325C, L330R, and R466S variants with TLR8, but not the R525P substitution, indicating different disease mechanisms. Overall, these observations suggest that UNC93B1 mutations cause monogenic SLE or CBL due to differentially enhanced TLR7 and TLR8 signaling.


  • Idiopathic intracranial hypertension as the initial presenting manifestation of systemic lupus erythematosus in a child

    by Murugan Sudhakar, Anu P Kocheril, Anish S George, George I Vettiyil, Anitha Jasper, Sathish Kumar

    Idiopathic intracranial hypertension (IIH) is a diagnosis of exclusion characterized by features of raised intracranial pressure (ICP) in the absence of brain parenchymal lesion, vascular malformations, hydrocephalus, or central nervous system (CNS) infection. Commonly used other terms for this entity include benign intracranial hypertension (BIH) or pseudotumor cerebri. Few case reports of systemic lupus erythematosus (SLE) presenting as IIH are available in the literature. We report a 12-year-old girl presented with chronic holocranial headache and occasional episodes of projectile vomiting for the last 6 months and then developed blurring of vision for the last month. She fulfilled the criteria for IIH. Subsequent evaluation revealed a diagnosis of SLE. The occurrence of IIH in SLE is not coincidental and is reported in 1%–5.4% of patients with SLE. Though corticosteroids have not been widely used in IIH, underlying SLE warranted administering corticosteroids with subsequent complete resolution of IIH. Pediatricians, neurologists, intensivists, and ophthalmologists should consider SLE as a differential diagnosis in children presenting with IIH.


  • Performance of the QuantiFERON- TB gold test in children receiving immunosuppressive therapy for rheumatic diseases

    by Samantha Cheryl Kumar, George Ipe Vettiyal, Winsley Rose, Joy Michael, J Visalakshi, Sathish Kumar

  • Juvenile Idiopathic Arthritis

    by Murugan Sudhakar, Sathish Kumar

    Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children. The International League of Associations for Rheumatology (ILAR) has defined JIA as “arthritis of unknown etiology persisting for ≥6 wk with an onset at <16 y of age, after excluding other causes of joint inflammation”. Synovial inflammation is the result of a complex interplay of aberrant immune systems (both adaptive and innate) in a genetically susceptible individual, with possible external stimuli/triggers. Diagnosis of JIA essentially remains clinical, and laboratory investigations usually help to assess the severity of disease activity. Few investigations like antinuclear antibodies (ANA), human leukocyte antigen (HLA)-B27, and rheumatoid factor (RF) help to categorize or prognosticate a child with JIA. Timely use of effective therapeutic interventions including biological has shown good long-term outcomes of JIA.


  • Clinical profile of anti-NXP-2 antibody-positive inflammatory myositis and outcome in an Indian population

    by Abhilasha Manwatkar, Shivraj Padiyar, Aswin Nair, Avanish Jha, Sathish Kumar, Bijesh Yadav, John Antony Jude Prakash, John Kumar Das, John Mathew

    Introduction Myositis-specific antibodies (MSA) play an important role in the clinical presentation and prognosis of patients with idiopathic inflammatory myositis (IIM). Anti-NXP-2 is one of the newly described MSA. Objective We aimed to describe various clinical presentations associated with anti-NXP2 antibodies and assess response to treatment. Methods In this retrospective study, the electronic medical records of all patients who tested positive for anti-NXP2 during June 2019 to April 2022 were screened. Details of demography, clinical presentation, and treatment data were recorded. The anti-NXP2 was tested using the Euro line test kit. Any patient who had an intensity of ≥1+ was considered testing positive. The diagnosis of IIM was reviewed after applying the 2017 European League of Rheumatology (EULAR)/American College of Rheumatology (ACR) criteria of myositis. Results Among the 660 suspected patients, 470 (71.2%) patients were positive for IIM, and 28 (5.95%) patients were positive for anti-NXP2. From anti-NXP2-antibody positive, 21/470 (4.46%) patients fulfilled criteria for IIM. Among 12 adult (57.14%) patients with IIM, 7 (58.33%) presented as polymyositis (PM) and 5 (41.6%) as dermatomyositis (DM) with median age at presentation of 45 (IQR: 25–58) years. Calcinosis and subcutaneous oedema were observed in 4 (19%) and 2 (9.52%), respectively; myalgia in 6 (28.6%); and distal muscle weakness in 5 (23.8%) patients. Malignancy at the time of diagnosis was observed in two adults with IIM (16.7%), one with DM (intraductal breast cancer), and another with PM (anaplastic large cell lymphoma). Remaining, 9 had juvenile dermatomyositis (JDM) with a median age of 4 (IQR: 3–8) years. Seven (77.8%) patients with JDM had skin rash specific for DM (heliotrope rash and Gottron’s papule). None of the patients had cardiac and lung involvement, while GI symptoms, especially dysphagia, were present in 5 (23.8%) patients. During a median follow-up of 19 months (IQR: 12–26 months), 19/19 patients reported improvement and were in remission with treatment. Conclusion The current study shows that adult DM patients with anti-NXP-2 autoantibodies have a unique clinical phenotype. Its presentation differs between adult and JDM, even in different parts of the world. Muscle weakness is mild and responds to treatment. Dysphagia needs more time and aggressive IS for improvement as compared to other muscle involvement. Key Points • Anti-NXP-2 antibody presentation varied from adult to child, as in different parts of the world. • In Indian adult patients, non-specific skin manifestations were more common, whereas in JDM, specific skin features were common. • There was less likely involvement of the lung and heart. But more risk of GI involvement requiring aggressive management. • Adult with anti-NXP-2 antibody should be screened for malignancy at the time of presentation.


  • Open Access

    Autoantibodies in Pediatric Systemic Lupus Erythematosus: Cluster Analysis and its Clinical Implications in Indian Children

    by Siva Vyasam, Anu Punnen, Visalakshi Jeyaseelan, John Jude Prakash, Sathish Kumar


  • MRI Patterns in Pediatric CNS Hemophagocytic Lymphohistiocytosis

    by P. Malik, L. Antonini, P. Mannam, F.N. Aboobacker, A. Merve, K. Gilmour, K. Rao, S. Kumar, S.E. Mani, D. Eleftheriou, et al.

    BACKGROUND AND PURPOSE: Neuroimaging has an important role in detecting CNS involvement in children with systemic or CNS isolated hemophagocytic lymphohistiocytosis. We characterized a cohort of pediatric patients with CNS hemophagocytic lymphohistiocytosis focusing on neuroradiologic features and assessed whether distinct MR imaging patterns and genotype correlations can be recognized. MATERIALS AND METHODS: We retrospectively enrolled consecutive pediatric patients diagnosed with hemophagocytic lymphohistiocytosis with CNS involvement treated at 2 pediatric neurology centers between 2010 and 2018. Clinical and MR imaging data were analyzed. RESULTS: Fifty-seven children (40 primary, 70%) with a median age of 36 months (interquartile range, 5.5–80.8 months) were included. One hundred twenty-three MR imaging studies were assessed, and 2 broad imaging patterns were identified. Pattern 1 (significant parenchymal disease, 32/57, 56%) was seen in older children (P = .004) with worse clinical profiles. It had 3 onset subpatterns: multifocal white matter lesions (21/32, 66%), brainstem predominant disease (5, 15%), and cerebellitis (6, 19%). All patients with the brainstem pattern failed to meet the radiologic criteria for chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids. An attenuated imaging phenotype (pattern 2) was seen in 25 patients (44%, 30 studies) and was associated with younger age. CONCLUSIONS: Distinct MR imaging patterns correlating with clinical phenotypes and possible genetic underpinnings were recognized in this cohort of pediatric CNS hemophagocytic lymphohistiocytosis. Disruptive mutations and missense mutations with absent protein expression correlate with a younger onset age. Children with brainstem and cerebellitis patterns and a negative etiologic work-up require directed assessment for CNS hemophagocytic lymphohistiocytosis.


  • Top Cited Papers

    Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations and management

    by Jayakanthan Kabeerdoss, Rakesh Kumar Pilania, Reena Karkhele, T. Sathish Kumar, Debashish Danda, Surjit Singh

    Multisystem inflammatory syndrome (MIS-C) is a pediatric hyperinflammation disorder caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). It has now been reported from several countries the world over. Some of the clinical manifestations of MIS-C mimic Kawasaki disease (KD) shock syndrome. MIS-C develops 4–6 weeks following SARS-CoV-2 infection, and is presumably initiated by adaptive immune response. Though it has multisystem involvement, it is the cardiovascular manifestations that are most prominent. High titres of anti-SARS-CoV-2 antibodies are seen in these patients. As this is a new disease entity, its immunopathogenesis is not fully elucidated. Whether it has some overlap with KD is still unclear. Current treatment guidelines recommend use of intravenous immunoglobulin and high-dose corticosteroids as first-line treatment. Mortality rates of MIS-C are lower compared to adult forms of severe COVID-19 disease.


  • Open Access

    THU0298 Long term outcome of patients with takayasu arteritis- a single centre study

    by R Goel, D Danda, G Joseph, A Nair, V Jayseelan, L Jayaseelan, S Kumar, P Bacon

    Background Takayasu Arteritis (TA), a large vessel vasculitis is characterised by a variable clinical course and outcome that differs across populations. Most studies are limited by small sample size. Objectives (i) To study treatment outcome in our TA patients with a follow up of ≥12 months (ii) Construct a prediction model for subset of patients with sustained inactive disease. Methods Consecutive patients with TA attending our clinics between 1998 and April 2016 were recruited. Details of baseline demography, clinical profile, angiography, disease extent using DEI.Tak, laboratory parameters and TADS (Takayasu arteritis damage score) were recorded. At each follow up visit, disease activity was assessed by Indian Takayasu Activity score (ITAS-2010 (CRP) and imaging, while damage was assessed by TADS for patients who followed up for ≥12 months (retrospectively for 179 and prospectively for 72 patients). Treatment response was classified as complete response (CR), partial response and no-response. Sustained inactive disease was defined as maintenance of CR throughout the follow up with steroid dose reduced to ≤5mg/day. Relapse was defined as return of active disease after CR. Statistical analysis was performed using SPSS-16. Intergroup comparisons were performed by nonparametric test. Logistic regression was used for determining independent associations. Optimal cut off values were determined using receiver operating curve and prediction model was constructed. Efficacy of medications was compared by Cox proportional hazards model. Results Baseline details were noted for 503 patients: mean age at onset of 25.6±11.1 years, disease duration 12 (6–48) months, diagnostic delay 6 (3–24) months) and 77.9% were females. Among 251 patients with follow up of at least 12 months, 95.2% received steroids along with II line immunosuppressant in 93.6% (mycophenolate in 63.7%). Tocilizumab was given induction or rescue therapy to 44 patients. Revascularisation procedures were performed in 71.7%. Complete (ITAS 2010 = 0, CRP Conclusions Medical management arrested disease activity, damage progression and mortality in our cohort. Low baseline CRP and DEI.Tak scores and type 4 disease independently predicted sustained inactive disease. Disclosure of Interest None declared